Cabometyx (cabozantinib) — United Healthcare
Endometrial Carcinoma
Initial criteria
- Diagnosis of endometrial carcinoma
- Used as second-line or subsequent treatment
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Cabometyx therapy
Approval duration
12 months